Last reviewed · How we verify
NCT06123429
Mindfulness in Hidradenitis Suppurativa
NA trial testing Mindfulness Based Stress reduction in Hidradenitis Suppurativa in 25 participants. Completed in 30 May 2024.
30 April 2024
Quick facts
| Lead sponsor | University of Arkansas |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | other |
| Enrollment | 25 |
| Start date | 3 October 2023 |
| Primary completion | 30 April 2024 |
| Estimated completion | 30 May 2024 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Mindfulness Based Stress reduction
Conditions studied
- Hidradenitis Suppurativa — all drugs for Hidradenitis Suppurativa →
Sponsor
University of Arkansas
Who can join
Adults 18 to 89, any sex, with Hidradenitis Suppurativa. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The study will investigate the impact of an 8-week-long Mindfulness-Based Stress Reduction course on quality of life and disease severity in patients with hidradenitis suppurativa (HS).
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06123429
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hidradenitis Suppurativa
Currently open trials in the same condition.
- NCT07244263 — A Study of Zasocitinib in Adults With Hidradenitis Suppurativa · Phase 2 · recruiting
- NCT07225569 — A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Sup · Phase 2 · recruiting
- NCT07243782 — Regulatory Post-Marketing Surveillance in Hidradenitis Suppurativa, Pediatric Plaque Psoriasis and JIA Treated With Cose · recruiting
- NCT07282015 — Real-world Secukinumab Outcomes in Canadian HS Patients · recruiting
- NCT07228390 — A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps · Phase 2 · recruiting
Other University of Arkansas trials
Trials by the same sponsor.
- NCT07029776 — MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple Myeloma · Phase 2 · not yet recruiting
- NCT07341399 — Essential Amino Acid Supplementation in Adult Spinal Deformity Patients · NA · not yet recruiting
- NCT07071766 — Improving Outcomes for Early Postpartum Mothers in Outpatient MOUD Treatment · NA · recruiting
- NCT05823727 — Effects of Collagen Peptide Supplementation on Connective Tissue Remodeling, Functional Outcomes, and Wound Healing Afte · NA · recruiting
- NCT06604065 — Essential Amino Acids and Parkinsons Disease · Phase 1 · withdrawn
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06123429 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Arkansas
- Last refreshed: 4 November 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06123429.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing